diaDexus recent weakness brings attractive entry point, says Ladenburg Ladenburg says the recent weakness in shares of diaDexus presents an attractive entry point into the name. The firm expects fundamentals of the company's Lp-PLA2 franchise to strengthen over the next 6-12 months and it reiterates a Buy rating on the stock with a $1.75 price target.
diaDexus receives FDA clearance for PLAC activity test diaDexus announced that it has received 510(k) clearance from the FDA for its PLAC Test for Lp-PLA2 Activity. This new test is an enzyme assay for the quantitative determination of Lp-PLA2 activity in human plasma and serum. An analysis based on REGARDS, a U.S.-based National Institutes of Health-funded longitudinal study, using a cohort of approximately 4,500 individuals with no prior history of cardiovascular events, demonstrated that elevated Lp-PLA2 Activity levels are associated with a significant increase for risk of coronary heart disease. To commercialize this new test, diaDexus will use its established salesforce. Beginning in 1Q15, the company expects to start contracting and enabling new lab customers.